We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Incyte (INCY) Announces Positive Data on Enzyme Inhibitor
Read MoreHide Full Article
Incyte Corporation (INCY - Free Report) recently announced that new data was published online from the ongoing trial, ECHO-202 by the American Society of Clinical Oncology (ASCO) in advance of its annual meeting in Chicago, IL, June 2–6, 2017.
The trial is evaluating Incyte’s selective IDO1 enzyme inhibitor, epacadostat, in combination with Merck’s (MRK - Free Report) anti-PD-1 therapy, Keytruda (pembrolizumab).
Patients previously treated with anti-PD-1 or anti-CTLA-4 therapies were excluded from this trial.
The data from the trial includes phase I/II efficacy and safety data from the following cohorts: non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), bladder cancer, squamous cell carcinoma of the head and neck (SCCHN), triple-negative breast cancer (TNBC), and ovarian cancer (OVC). The results from new data showed that epacadostat in combination with Keytruda was well-tolerated and preliminary efficacy outcomes for these cohorts demonstrate encouraging clinical activity, both within and across tumor types, which compares favorably with contemporary data in the second-line setting.
Concurrently, data from the ECHO-204 trial evaluated the safety and efficacy of epacadostat, in combination with Bristol-Myers Squibb’s (BMY - Free Report) PD-1 immune checkpoint inhibitor Opdivo. The results show that the combination was well-tolerated across the studied patients and demonstrates promising clinical responses, particularly in melanoma and with squamous cell carcinoma of the head and neck (SCCHN). The combination is also being evaluated ovarian cancer (OVC), and colorectal cancer (CRC).
Following the news Incyte’s shares gained 2.3%. Notably, in the past one year the company’s shares have rallied 68.8%, while the Zacks classified Medical - Biomedical and Genetics industry fell 5.8%.
The successful development of epacadostat will reduce the company’s dependence on Jakafi. Incyte’s dependence on a single product, Jakafi, for growth is concerning. Lower-than-expected sales would be a huge setback for the company.
While we are positive on the company’s efforts to expand Jakafi’s label, any development/regulatory setback could pull down the stock significantly. In Feb 2016, Incyte received a notice letter regarding an abbreviated new drug application seeking approval to market a generic version of Jakafi. Earlier-than-expected entry of generic versions of Jakafi would be a big blow for the company.
Zacks Rank & Key Pick
Incyte Corporation currently carries a Zacks Rank #4 (Sell).
VIVUS’s loss per share estimates narrowed from 50 cents to 39 cents for 2017, over the last 30 days. The company posted positive earnings surprises in all of the four trailing quarters with an average beat of 233.69%.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
Image: Bigstock
Incyte (INCY) Announces Positive Data on Enzyme Inhibitor
Incyte Corporation (INCY - Free Report) recently announced that new data was published online from the ongoing trial, ECHO-202 by the American Society of Clinical Oncology (ASCO) in advance of its annual meeting in Chicago, IL, June 2–6, 2017.
The trial is evaluating Incyte’s selective IDO1 enzyme inhibitor, epacadostat, in combination with Merck’s (MRK - Free Report) anti-PD-1 therapy, Keytruda (pembrolizumab).
Patients previously treated with anti-PD-1 or anti-CTLA-4 therapies were excluded from this trial.
The data from the trial includes phase I/II efficacy and safety data from the following cohorts: non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), bladder cancer, squamous cell carcinoma of the head and neck (SCCHN), triple-negative breast cancer (TNBC), and ovarian cancer (OVC). The results from new data showed that epacadostat in combination with Keytruda was well-tolerated and preliminary efficacy outcomes for these cohorts demonstrate encouraging clinical activity, both within and across tumor types, which compares favorably with contemporary data in the second-line setting.
Concurrently, data from the ECHO-204 trial evaluated the safety and efficacy of epacadostat, in combination with Bristol-Myers Squibb’s (BMY - Free Report) PD-1 immune checkpoint inhibitor Opdivo. The results show that the combination was well-tolerated across the studied patients and demonstrates promising clinical responses, particularly in melanoma and with squamous cell carcinoma of the head and neck (SCCHN). The combination is also being evaluated ovarian cancer (OVC), and colorectal cancer (CRC).
Following the news Incyte’s shares gained 2.3%. Notably, in the past one year the company’s shares have rallied 68.8%, while the Zacks classified Medical - Biomedical and Genetics industry fell 5.8%.
The successful development of epacadostat will reduce the company’s dependence on Jakafi. Incyte’s dependence on a single product, Jakafi, for growth is concerning. Lower-than-expected sales would be a huge setback for the company.
While we are positive on the company’s efforts to expand Jakafi’s label, any development/regulatory setback could pull down the stock significantly. In Feb 2016, Incyte received a notice letter regarding an abbreviated new drug application seeking approval to market a generic version of Jakafi. Earlier-than-expected entry of generic versions of Jakafi would be a big blow for the company.
Zacks Rank & Key Pick
Incyte Corporation currently carries a Zacks Rank #4 (Sell).
A better-ranked stock in the health care sector is VIVUS, Inc. which sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
VIVUS’s loss per share estimates narrowed from 50 cents to 39 cents for 2017, over the last 30 days. The company posted positive earnings surprises in all of the four trailing quarters with an average beat of 233.69%.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think. See This Ticker Free >>